

Tatjana S Potpara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/615248/publications.pdf>

Version: 2024-02-01

210
papers

18,274
citations

50244

46
h-index

14736

127
g-index

212
all docs

212
docs citations

212
times ranked

15035
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	1.5	25
2	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	0.7	9
3	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 778-786.	1.8	15
4	Stroke prevention in atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 501-510.	2.3	10
5	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	0.7	12
6	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 1001-1012.	1.0	15
7	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	1.7	10
8	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardiovascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
9	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 – epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
10	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
11	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
12	Adherence to the 4S-AF Scheme in the Balkan region: Insights from the BALKAN-AF survey. <i>Kardiologia Polska</i> , 2022, 80, 461-467.	0.3	0
13	Review of the guidelines of the European society of cardiology 2020 for the diagnosis and treatment of atrial fibrillation. , 2022, 1, 93-104.		0
14	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2022, 43, 2442-2460.	1.0	43
15	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Internal Medicine</i> , 2022, 103, 41-49.	1.0	5
16	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. <i>European Journal of Internal Medicine</i> , 2022, 101, 1-7.	1.0	27
17	Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. <i>BMJ Open</i> , 2022, 12, e059156.	0.8	3
18	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. <i>Annals of Medicine</i> , 2021, 53, 17-25.	1.5	18
20	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	0.7	74
21	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322.	0.7	9
22	Stroke prevention strategies in high-risk patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2021, 18, 276-290.	6.1	36
23	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
24	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
25	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	0.7	64
26	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021, 121, 270-278.	1.8	118
27	Long-Term Effects of Apixaban Confirmed in the Open-Label Extension of AVERROES Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 405-407.	1.8	0
28	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1061-1070.	0.9	6
29	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , 2021, 23, 806-814.	0.7	4
30	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN-AF survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14080.	0.8	3
31	Improvement of Maximal Exercise Performance After Catheter Ablation of Atrial Fibrillation and Its Prognostic Significance for Long-Term Rhythm Outcome. <i>Journal of the American Heart Association</i> , 2021, 10, e017445.	1.6	5
32	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021, 86, 1-11.	1.0	40
33	Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. <i>American Heart Journal</i> , 2021, 234, 31-41.	1.2	21
34	Importance of Dedicated Units for the Management of Patients With Inherited Arrhythmia Syndromes. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003313.	1.6	7
35	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
36	Obstructive sleep apnoea testing and management in atrial fibrillation patients: a joint survey by the European Heart Rhythm Association (EHRA) and the Association of Cardiovascular Nurses and Allied Professions (ACNAP). <i>Europace</i> , 2021, 23, 1677-1684.	0.7	24

#	ARTICLE	IF	CITATIONS
37	Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey. <i>Europace</i> , 2021, 23, 1502-1507.	0.7	2
38	How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1807-1810.	0.9	2
39	Current perspectives on wearable rhythm recordings for clinical decision-making: the wEHRables 2 survey. <i>Europace</i> , 2021, 23, 1106-1113.	0.7	30
40	Quality indicators in the management of atrial fibrillation: the BALKAN-AF survey. <i>International Journal of Cardiology</i> , 2021, 333, 105-109.	0.8	2
41	Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europeâ€™Comparison of the Results of Multi-Center Registries. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7178.	1.2	2
42	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
43	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. <i>Europace</i> , 2021, 23, 149-156.	0.7	14
44	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	1
45	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
46	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. <i>Europace</i> , 2020, 22, 33-46.	0.7	54
47	A novel risk model for very late return of atrial fibrillation beyond 1Â year after cryoballoon ablation: the SCALE-CryoAF score. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 209-217.	0.6	13
48	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2020, 22, 162-169.	0.7	26
49	Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. <i>Thrombosis and Haemostasis</i> , 2020, 120, 005-007.	1.8	4
50	Correspondence: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 265-266.	1.4	1
51	Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices. <i>Europace</i> , 2020, 22, 173-176.	0.7	4
52	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. <i>IJC Heart and Vasculature</i> , 2020, 26, 100461.	0.6	1
53	â€™Real-worldâ€™™ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020, 22, 831-832.	0.7	18
54	Smart device-based detection of atrial fibrillation: Opportunities and challenges in the emerging world of digital health. <i>International Journal of Cardiology</i> , 2020, 302, 108-109.	0.8	3

#	ARTICLE	IF	CITATIONS
55	The association between atrial fibrillation and Alzheimer's disease: fact or fallacy? A systematic review and meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 106-112.	0.6	24
56	The role of amiodarone in contemporary management of complex cardiac arrhythmias. <i>Pharmacological Research</i> , 2020, 151, 104521.	3.1	50
57	Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia. <i>Europace</i> , 2020, 22, 1788-1797.	0.7	18
58	Stroke risk stratification in hypertrophic cardiomyopathy. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 318-320.	0.4	1
59	Detection of Atrial Fibrillation on Stroke Units: Look Harder, Look Longer, Look in More Sophisticated Ways. <i>Cerebrovascular Diseases</i> , 2020, 49, 656-658.	0.8	1
60	Treatment implications of renal disease in patients with atrial fibrillation: The BALKANâ€AF survey. <i>Journal of Arrhythmia</i> , 2020, 36, 863-873.	0.5	2
61	Atrial fibrillation: Can it be as easy as CC to ABC?. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13413.	1.7	3
62	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. <i>Europace</i> , 2020, 22, 1567-1578.	0.7	23
63	What do we do about atrial high rate episodes?. <i>European Heart Journal Supplements</i> , 2020, 22, O42-O52.	0.0	29
64	Antithrombotic therapy: less is more or the more the better?â€Authorsâ€™ reply. <i>Europace</i> , 2020, 22, 1143-1143.	0.7	0
65	Contemporary management of patients with syncope in clinical practice: an EHRA physician-based survey. <i>Europace</i> , 2020, 22, 980-987.	0.7	14
66	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20Âyears. <i>Internal and Emergency Medicine</i> , 2020, 15, 1183-1192.	1.0	25
67	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. <i>Circulation</i> , 2020, 141, 1855-1858.	1.6	2
68	Regional registries on the management of atrial fibrillation: Essential pieces in the global puzzle. <i>IJC Heart and Vasculature</i> , 2020, 26, 100473.	0.6	2
69	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 357-365.	1.0	3
70	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020, 133, 1328-1335.	0.6	15
71	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. <i>Europace</i> , 2020, 22, 833-838.	0.7	11
72	Factors influencing the use of leadless or transvenous pacemakers: results of the European Heart Rhythm Association Prospective Survey. <i>Europace</i> , 2020, 22, 667-673.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020, 22, 496-505.	0.7	29
74	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 348-357.	0.4	39
75	Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKAN-AF survey. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13200.	1.7	5
76	Stroke prevention in atrial fibrillation: comparison of recent international guidelines. <i>European Heart Journal Supplements</i> , 2020, 22, O53-O60.	0.0	12
77	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 47-58.	0.3	11
78	Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 187-195.	0.3	12
79	A square root pattern of changes in heart rate variability during the first year after circumferential pulmonary vein isolation for paroxysmal atrial fibrillation and their relation with long-term arrhythmia recurrence. <i>Kardiologia Polska</i> , 2020, 78, 209-218.	0.3	10
80	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Kardiologia Polska</i> , 2020, 78, 105-116.	0.3	9
81	Risk factor modification for the primary and secondary prevention of atrial fibrillation. Part 1. <i>Kardiologia Polska</i> , 2020, 78, 181-191.	0.3	5
82	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. <i>Kardiologia Polska</i> , 2020, 78, 512-519.	0.3	1
83	Mineralocorticoid receptor antagonists and prevention of atrial fibrillation in patients with hypertension. Authors' reply. <i>Kardiologia Polska</i> , 2020, 78, 610-611.	0.3	0
84	Clinical approach to the patient with Brugada Syndrome: risk stratification and optimal management. <i>Panminerva Medica</i> , 2020, 61, 473-485.	0.2	0
85	Risk factor modification for the primary and secondary prevention of atrial fibrillation. Part 2. <i>Kardiologia Polska</i> , 2020, 78, 192-202.	0.3	3
86	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	0.7	72
87	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 150-152.	2.3	1
88	Validation of the MB-LATER score for prediction of late recurrence after catheter-ablation of atrial fibrillation. <i>International Journal of Cardiology</i> , 2019, 276, 130-135.	0.8	18
89	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society. <i>Europace</i> , 2019, 21, 192-193.	0.7	209
90	Triple or dual antithrombotic therapy post-percutaneous coronary intervention: Which one is better?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2473-2474.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Physiciansâ€™ Perceptions of Their Patientsâ€™ Attitude and Knowledge of Long-Term Oral Anticoagulant Therapy in Bulgaria. <i>Medicina (Lithuania)</i> , 2019, 55, 313.	0.8	2
92	SERUM cardiacâ€specific biomarkers and atrial fibrillation in myotonic dystrophy type I. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2914-2919.	0.8	3
93	Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drugâ€drug interaction. <i>European Heart Journal</i> , 2019, 40, 3802-3802.	1.0	2
94	Very late arrhythmia recurrences in patients with sinus rhythm within the first year after catheter ablation: The Leipzig Heart Center AF Ablation Registry. <i>Europace</i> , 2019, 21, 1646-1652.	0.7	2
95	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
96	Sex-related risks of recurrence of atrial fibrillation after ablation: Insights from the Guangzhou Atrial Fibrillation Ablation Registry. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 171-179.	0.7	6
97	Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 420-429.	0.7	13
98	Using Blood Biomarkers to Identify Atrial Fibrillationâ€Related Stroke. <i>Stroke</i> , 2019, 50, 1956-1957.	1.0	4
99	Letter by Guo et al Regarding Article, â€Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trialâ€. <i>Circulation</i> , 2019, 139, e1037-e1038.	1.6	1
100	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
101	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	0.7	10
102	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
103	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
104	Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation. <i>Clinical Cardiology</i> , 2019, 42, 320-329.	0.7	24
105	Challenges in clinical decision-making on concomitant drug therapies in patients with atrial fibrillation taking oral anticoagulants. <i>European Heart Journal</i> , 2019, 40, 1569-1570.	1.0	6
106	Stroke Risk Stratification: CHA2DS2-VA or CHA2DS2-VASc?. <i>Heart Lung and Circulation</i> , 2019, 28, e14-e15.	0.2	10
107	Meeting the unmet needs to improve management and outcomes of patients with atrial fibrillation: fitting global solutions to local settings. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 574-576.	0.3	2
108	Integrating multiple aspects of care for better management of atrial fibrillation: teamwork between physicians and patients. <i>Kardiologia Polska</i> , 2019, 77, 415-416.	0.3	1

#	ARTICLE	IF	CITATIONS
109	Comparing Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) to Different Coumadins: The Win-Win Scenarios. <i>Thrombosis and Haemostasis</i> , 2018, 118, 803-805.	1.8	7
110	Contemporary stroke prevention strategies in 11% European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	0.7	118
111	Optimizing bleeding risk assessment in patients with atrial fibrillation: To score or not to score?. <i>International Journal of Cardiology</i> , 2018, 254, 164-166.	0.8	0
112	Antiarrhythmic drugs—clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732an.	0.7	144
113	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1404-1406.	1.0	10
114	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
115	Patients'™ knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2018, 20, 386-391.	0.7	35
116	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	4.1	89
117	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018, 15, e37-e60.	0.3	21
118	Predicting recurrent atrial fibrillation after catheter ablation. <i>Europace</i> , 2018, 20, f460-f461.	0.7	5
119	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	0.7	75
120	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2018, 20, 895-896.	0.7	24
121	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
122	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
123	Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2014-2017.	1.8	39
124	A U-shaped relationship of body mass index on atrial fibrillation recurrence post ablation: A report from the Guangzhou atrial fibrillation ablation registry. <i>EBioMedicine</i> , 2018, 35, 40-45.	2.7	22
125	Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). <i>Europace</i> , 2018, 20, 1218-1224.	0.7	18
126	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2018, 20, 1565-1565ao.	0.7	186

#	ARTICLE	IF	CITATIONS
127	The Challenge of Thromboprophylaxis in Cancer Patientsâ€”Balancing the Thrombotic and Bleeding Risks. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1347-1349.	1.8	4
128	Predicting incident atrial fibrillation in patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2018, 269, 194-195.	0.8	1
129	The relationship of early recurrence of atrial fibrillation and the 3-month integrity of the ablation lesion set. <i>Scientific Reports</i> , 2018, 8, 9875.	1.6	19
130	Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project. <i>International Journal of Clinical Practice</i> , 2018, 72, e13247.	0.8	13
131	Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey. <i>Kardiologia Polska</i> , 2018, 76, 1507-1515.	0.3	2
132	Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: The MB-LATER clinical score. <i>Scientific Reports</i> , 2017, 7, 40828.	1.6	71
133	Postapproval Observational Studies of Nonâ€”Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1115.	3.8	35
134	Drug-induced liver injury with oral anticoagulants: a threat or not?. <i>Heart</i> , 2017, 103, 809-811.	1.2	7
135	Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2017, 33, 1175-1177.	0.9	3
136	Sex-related differences in atrial fibrillation: can we discern true disparities from biases?. <i>Heart</i> , 2017, 103, 979-981.	1.2	6
137	Brugada syndrome: A general cardiologist's perspective. <i>European Journal of Internal Medicine</i> , 2017, 44, 19-27.	1.0	32
138	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y Electrofisiologaa (SOLEACE). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 235-250.	1.4	50
139	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y Electrofisiologaa (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
140	Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. <i>Clinical Research in Cardiology</i> , 2017, 106, 813-823.	1.5	61
141	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <i>American Journal of Medicine</i> , 2017, 130, 773-779.	0.6	6
142	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <i>Advances in Therapy</i> , 2017, 34, 357-377.	1.3	14
143	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. <i>Advances in Therapy</i> , 2017, 34, 2274-2294.	1.3	6
144	Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2017, 19, 1737-1742.	0.7	34

#	ARTICLE	IF	CITATIONS
145	Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 1896-1902.	0.7	53
146	Persistency of left atrial linear lesions after radiofrequency catheter ablation for atrial fibrillation: Data from an invasive follow-up electrophysiology study. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1403-1414.	0.8	13
147	Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians. <i>Advances in Therapy</i> , 2017, 34, 1897-1917.	1.3	102
148	Approach to cardio-oncologic patients with special focus on patients with cardiac implantable electronic devices planned for radiotherapy: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 1579-1584.	0.7	15
149	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	1.3	17
150	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. <i>Nature Reviews Cardiology</i> , 2017, 14, 701-714.	6.1	98
151	External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2017, 130, 1464.e13-1464.e21.	0.6	25
152	Stroke prevention in atrial fibrillation: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1230-1239.	1.8	346
153	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Antithrombotic Therapy in Atrial Fibrillation Associated With Valvular Heart Disease. <i>Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRs), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es.</i> <i>Thrombosis and Haemostasis</i> , 2017, 117, 2215-2236.	0.7	107
154	Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 42.	1.8	41
155	Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 42.	1.3	11
156	Left atrial appendage closure with Watchman device in prevention of thromboembolic complications in patients with atrial fibrillation: First experience in Serbia. <i>Vojnosanitetski Pregled</i> , 2017, 74, 378-385.	0.1	0
157	Stroke prevention in atrial fibrillation and "real world" adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	1.6	40
158	Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). <i>Europace</i> , 2016, 18, 778-784.	0.7	19
159	Management and Outcome of Periprocedural Cardiac Perforation and Tamponade with Radiofrequency Catheter Ablation of Cardiac Arrhythmias: A Single Medium-Volume Center Experience. <i>Advances in Therapy</i> , 2016, 33, 1782-1796.	1.3	23
160	Stroke prevention in atrial fibrillation. <i>Lancet, The</i> , 2016, 388, 806-817.	6.3	329
161	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	18
162	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16016.	18.1	185

#	ARTICLE	IF	CITATIONS
163	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of "valvular" atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1593-1598.	0.7	13
164	Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association and Canadian Heart Rhythm Society. <i>Europace</i> , 2016, 18, 1880-1885.	0.7	10
165	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1113-1116.	0.7	12
166	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 463-467.	0.7	49
167	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 355-383.	0.5	233
168	The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2016, 18, 146-150.	0.7	60
169	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
170	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 151-155.	0.7	50
171	Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Current Medicinal Chemistry</i> , 2016, 23, 2055-2069.	1.2	3
172	Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy. <i>Current Medicinal Chemistry</i> , 2016, 23, 2070-2083.	1.2	11
173	Management of paediatric arrhythmias in Europe: authors' reply. <i>Europace</i> , 2015, 17, 1879.2-1880.	0.7	0
174	Dabigatran in "real-world" clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1093-1098.	1.8	22
175	Relation of Biomarkers of Inflammation and Oxidative Stress with Hypertension Occurrence in Lone Atrial Fibrillation. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	16
176	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 819-824.	0.7	14
177	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	0.7	119
178	Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1862-1867.	0.7	24
179	EHRA research network surveys: 6 years of EP wires activity. <i>Europace</i> , 2015, 17, 1733-1738.	0.7	0
180	How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 468-472.	0.7	27

#	ARTICLE	IF	CITATIONS
181	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
182	Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 177-194.	1.6	38
183	Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). <i>Europace</i> , 2015, 17, 986-993.	0.7	38
184	Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 642-646.	0.7	77
185	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. <i>Europace</i> , 2015, 17, 507-508.	0.7	20
186	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRs). <i>Europace</i> , 2015, 17, 1197-1214.	0.7	160
187	Patterns in atrial fibrillation management and "real-world" adherence to guidelines in the Balkan Region: an overview of the Balkan atrial fibrillation survey. <i>European Heart Journal</i> , 2015, 36, 1943-4.	1.0	8
188	Personnel, equipment, and facilities for electrophysiological and catheter ablation procedures in Europe: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1078-1082.	0.7	7
189	How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. <i>Europace</i> , 2014, 16, 1852-1856.	0.7	24
190	Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1521-1523.	0.7	12
191	Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 293-298.	0.7	32
192	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
193	Use of event recorders and loop recorders in clinical practice: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1384-1386.	0.7	28
194	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 698-702.	0.7	7
195	The Association of CHA2DS2-VASc Score and Blood Biomarkers with Ischemic Stroke Outcomes: The Belgrade Stroke Study. <i>PLoS ONE</i> , 2014, 9, e106439.	1.1	16
196	Endothelial (Dys)Function in Lone Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2014, 21, 622-645.	0.9	20
197	Catheter Ablation of Lone Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2014, 21, 591-612.	0.9	13
198	Novel oral anticoagulants in non-valvular atrial fibrillation. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 115-129.	0.7	27

#	ARTICLE	IF	CITATIONS
199	A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: The Belgrade Atrial Fibrillation Study. <i>International Journal of Cardiology</i> , 2013, 168, 4744-4749.	0.8	95
200	Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. <i>European Journal of Heart Failure</i> , 2013, 15, 415-424.	2.9	51
201	Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. <i>Patient Preference and Adherence</i> , 2013, 7, 835.	0.8	4
202	Reliable Identification of "Truly Low" Thromboembolic Risk in Patients Initially Diagnosed With "Lone" Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 319-326.	2.1	101
203	A 12-Year Follow-up Study of Patients With Newly Diagnosed Lone Atrial Fibrillation. <i>Chest</i> , 2012, 141, 339-347.	0.4	136
204	Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: The Belgrade atrial fibrillation study. <i>International Journal of Cardiology</i> , 2012, 161, 39-44.	0.8	64
205	New anticoagulant treatments to protect against stroke in atrial fibrillation. <i>Heart</i> , 2012, 98, 1341-1347.	1.2	39
206	Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban. <i>Advances in Therapy</i> , 2012, 29, 491-507.	1.3	29
207	Mitral Annular Calcification Predicts Cardiovascular Morbidity and Mortality in Middle-aged Patients With Atrial Fibrillation. <i>Chest</i> , 2011, 140, 902-910.	0.4	43
208	Ischemic Stroke and Atrial Fibrillation " A Deadly Serious Combination. <i>Cerebrovascular Diseases</i> , 2011, 32, 461-462.	0.8	11
209	Lone Atrial Fibrillation: Where Are We Now?. <i>Hospital Practice (1995)</i> , 2011, 39, 17-31.	0.5	9
210	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10%220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> , 0, , .	0.8	3